494. Real-world effectiveness of tixagevimab/cilgavimab for COVID-19 pre-exposure prophylaxis in solid organ transplant recipients during the Omicron variant period

BACKGROUND: Pre-exposure prophylaxis (PrEP) with a combination of long-acting monoclonal antibodies with tixagevimab/cilgavimab (T/C) have provided viral neutralizing activity against SARS-CoV-2 and protected solid organ transplant recipients (SOTRs) that produced poor immunogenicity after COVID-19...

Descripción completa

Detalles Bibliográficos
Autores principales: Rojanakit, Gun, Kiertiburanakul, Sasisopin, Boongird, Sarinya, Sutharattanapong, Napan, Yingchoncharoen, Teerapat, Sobhonslidsuk, Abhasnee, Bruminhent, Jackrapong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678462/
http://dx.doi.org/10.1093/ofid/ofad500.563

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678462/
http://dx.doi.org/10.1093/ofid/ofad500.563

Ejemplares similares